Epidemiological Research on SARS-CoV-2 (novel coronavirus) Antibody Positivity Rate among Healthcare Workers at Saitama Medical Center, Jichi Medical University during the COVID-19 Pandemic

Epidemiological Research on SARS-CoV-2 (novel coronavirus) Antibody Positivity Rate among Healthcare Workers at Saitama Medical Center, Jichi Medical University during the COVID-19 Pandemic - Epidemiological Research on SARS-CoV-2 Antibody Positivity Rate among Healthcare Workers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044648

Enrollment

Registered

2021-06-30

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy medical personnel who are engaged in this hospital including junior resident, physicians in general medicine department, physicians in emergency department, physicians ICU, EICU nurses, emergency and ward 2A nurses who have given consent for this research, who have been or will be engaged in the treatment of SARS-COV-2 infected patients

Exclusion criteria

Exclusion criteria: Those with fever, cough, or respiratory distress at the time of the initial examination, and those who do not consent to the research.

Design outcomes

Primary

Measure	Time frame
The primary outcome is the rate of antibody positivity in the entire research population, and the change in the rate of positivity	—

Secondary

Measure	Time frame
The secondary outcome is the detection of significant differences in each factor among antibody-positive and antibody-negative subjects (age, sex, place of residence, department, the presence of COVID19 in the patient in charge if not an early resident, travel history in the past year, access to cluster-infected areas, the presence of cold symptoms and fever within 3 months), and subsequent incidence of COVID-19 in antibody-positive individuals.	—

Measure

Time frame

The secondary outcome is the detection of significant differences in each factor among antibody-positive and antibody-negative subjects (age, sex, place of residence, department, the presence of COVID19 in the patient in charge if not an early resident, travel history in the past year, access to cluster-infected areas, the presence of cold symptoms and fever within 3 months), and subsequent incidence of COVID-19 in antibody-positive individuals.

—

Countries

Japan

Contacts

Public ContactHitoshi Sugawara

saitama medical center, jichi medical university General Medicine

hsmdfacp@jichi.ac.jp0486472111

Outcome results